Last reviewed · How we verify
Treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Tice Bcg | bacillus-calmette-guerin | Pfizer | Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC] | Mycobacterium tuberculosis |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder:
- Treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder treatment updates — RSS
- Treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder treatment updates — Atom
- Treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder treatment updates — JSON
Cite this brief
Drug Landscape (2026). Treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-and-prophylaxis-of-carcinoma-in-situ-cis-of-the-urinary-bladder. Accessed 2026-06-10.
Related
- Treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing